Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point
Open Access
- 13 May 2020
- journal article
- research article
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 6 (2) , e19199
Abstract
Real-world drug repurposing—the immediate “off-label” prescribing of drugs to address urgent clinical needs—is a widely overlooked opportunity. Off-label prescribing (ie, for a nonapproved indication) is legal in most countries and tends to shift the burden of liability and cost to physicians and patients, respectively. Nevertheless, health crises may mean that real-world repurposing is the only realistic source for solutions. Optimal real-world repurposing requires a track record of safety, affordability, and access for drug candidates. Although thousands of such drugs are already available, there is no central repository of off-label uses to facilitate immediate identification and selection of potentially useful interventions during public health crises. Using the current coronavirus disease (COVID-19) pandemic as an example, we provide a glimpse of the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and targeted toward the underlying pathophysiology that makes COVID-19 so deadly. This paper briefly summarizes why cimetidine or famotidine, dipyridamole, fenofibrate or bezafibrate, and sildenafil citrate are worth considering for patients with COVID-19. Clinical trials to assess efficacy are already underway for famotidine, dipyridamole, and sildenafil, and further trials of all these agents will be important in due course. These examples also reveal the unlimited opportunity to future-proof our health care systems by proactively mining, synthesizing, cataloging, and evaluating the off-label treatment opportunities of thousands of safe, well-established, and affordable generic drugs.Keywords
All Related Versions
This publication has 59 references indexed in Scilit:
- Cimetidine augments Th1/Th2 dual polarized immune responses to recombinant HBV antigensVaccine, 2011
- Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate–activated protein kinase activationMetabolism, 2011
- Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial CellsCerebrovascular Diseases, 2010
- Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cellsBiochemical and Biophysical Research Communications, 2008
- Translational Therapeutics of DipyridamoleArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetesDiabetic Medicine, 2008
- CTAD as a universal anticoagulantJournal of Analytical Methods in Chemistry, 2003
- The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agentsLife Sciences, 1996
- The effect of cimetidine on platelet function: a study involving gastric fluid measurementsInflammation Research, 1986
- Cimetidin und Ranitidin bei Intensivpatienten: Doppelblinde randomisierte Cross-over-Studie zur intravenösen Gabe: Hämodynamik, plasmatische Gerinnung, Blutgase und Säure-Basen-StatusDMW - Deutsche Medizinische Wochenschrift, 1985